Analysts anticipate that U.S. prices for new obesity treatment pills from Eli Lilly and Novo Nordisk will match those of existing weight-loss injections. This marks a significant shift from the traditional practice of introducing new medications at higher prices. As the market evolves, investors should monitor these developments closely, as pricing strategies could have considerable implications for both companies and consumers.